A relationship between linezolid-induced myelosuppression and blood linezolid concentrations in methicillin-resistant staphylococcus aureus (MRSA) infection; an open-label, non-randomized study
Not Applicable
- Conditions
- MRSA infection
- Registration Number
- JPRN-UMIN000004322
- Lead Sponsor
- Kanazawa University Hospital
- Brief Summary
Our clinical study indicated that multiple doses of rifampicin (RFP) reduced the dose-normalized trough concentration of linezolid (LZD) at the first assessment day by an average of 65%.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
1) history of hypersensitivity to ZYVOX 2) pregnancy, parturition or lactation 3) other situation that doctor decides
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A relationship between linezolid-induced myelosuppression and serum linezolid concentrations
- Secondary Outcome Measures
Name Time Method Blood concentration-time profile of major metabolites in patients Urinary excretion amounts of linezolid and major metabolites in patients